Targeted therapy in renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Clinical Trials

Background:

• Hypoxia-regulated genes, including vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), are crucial for renal cell carcinoma (RCC) tumor progression.
• Targeted therapies inhibiting these pathways are being investigated in clinical trials for advanced or metastatic RCC.

Purpose of the Study:

• To review the efficacy of various targeted therapies in advanced or metastatic renal cell carcinoma (RCC).
• To explore the potential of predictive biomarkers to enhance treatment response and clinical benefit.

Main Methods:

• Review of clinical trial data for targeted therapies in advanced/metastatic RCC.
• Analysis of drugs targeting VEGF, EGF, and other tyrosine kinases, as well as mTOR inhibitors.
• Examination of outcomes including objective response rates and progression-free survival.

Main Results:

• Anti-VEGF antibody therapy demonstrated a delay in disease progression.
• Small-molecule inhibitors like sunitinib showed a 40% objective response rate.
• Sorafenib, a multi-tyrosine kinase inhibitor, yielded a 2% response rate but improved progression-free survival.
• Other agents like EGF receptor inhibitors showed limited objective responses.

Conclusions:

• Targeted therapies targeting angiogenesis and other pathways offer clinical benefits in advanced RCC.
• Identifying predictive factors, such as von Hippel-Lindau gene mutations, may personalize treatment and improve outcomes.
• Further Phase III trials combining targeted therapies could establish new standards of care for RCC.